Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for SARTF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SARTF and 80,000+ other tickers.
See exactly how SARTF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SARTF and 80,000+ other tickers.
Sartorius AG engages in the provision of solutions for biopharmaceutical research. It operates through following divisions: Bioprocess Solutions (BPS), and Lab Products and Service (LPS). The Bioprocess Solutions division focuses on single-use solutions, helps customers manufacture biotech medications and vaccines safely and efficiently. The Lab Products and services division serves the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The company was founded by Florence Sartorius, Sr. in 1870 and is headquartered in Goettingen, Germany.
Sartorius (OTCMKTS:SARTF - Get Free Report) and Integra LifeSciences (NASDAQ: IART - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings and institutional ownership. Insider and Institutional Ownership 84.8% of Integra LifeSciences shares
Sartorius Aktiengesellschaft (SOAGY) Analyst/Investor Day Transcript
Sartorius Aktiengesellschaft (SOAGY) Q4 2025 Earnings Call Transcript
Sartorius (OTCMKTS:SARTF - Get Free Report) and ClearPoint Neuro (NASDAQ: CLPT - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability. Earnings and Valuation This table compares Sartorius and ClearPoint
Sartorius AG (SARTF) is rebounding with strong bioprocess segment growth and improving profit margins, despite a challenging biopharma environment. Secular demand for biologics and increased manufacturing complexity drive long-term growth, supported by industry capex and geopolitical reshoring trends. SARTF's financials show revenue and EBITDA growth, but high leverage and potential dilution remain key risks for investors to monitor.